Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

For patients with newly diagnosed multiple myeloma (NDMM) receiving dexamethasone induction, dose reductions do not ne ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with ...

Dr. Susumu Hijioka spoke about the benefit of this combination therapy in patients with unresectable or recurrent GEP-NETs, ...

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin ...

JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management (CGEM – Research Report) today and set a price target of ...